<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VETMEDIN- pimobendan tablet, chewable </strong><br>Boehringer Ingelheim Vetmedica, Inc.<br></p></div>
<h1>
<span class="Bold">Vetmedin</span>® (pimobendan)<br><span class="Bold">Chewable Tablets</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf65d03c-5fed-43d7-b86c-b527ebc3f7b0"></a><a name="section-1"></a><p></p>
<p class="First">NADA 141-273, Approved by FDA</p>
<p>Cardiac drug for oral use in dogs only </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_421d6ff9-851c-42be-b9dc-38ff086f437d"></a><a name="section-2"></a><p></p>
<h1>Caution:</h1>
<p class="First">Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_b2271eed-f1ca-4018-a4bd-129ce46730f8"></a><a name="section-3"></a><p></p>
<h1>Description:</h1>
<p class="First">Vetmedin (pimobendan) is supplied as oblong half-scored chewable tablets containing 1.25, 2.5, 5 or 10 mg pimobendan per tablet.  Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic drug with vasodilatative properties.  Pimobendan exerts a stimulatory myocardial effect by a dual mechanism of action consisting of an increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (Type III).  Pimobendan exhibits vasodilating activity by inhibiting phosphodiesterase III activity.  The chemical name of pimobendan is 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazole-5-yl]-5-methyl-3(2H)-pyridazinone.  The structural formula of pimobendan is: </p>
<div class="Figure">
<a name="id2955133"></a><img alt="Picture of structural formula of pimobendan" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5441e5b2-cdc0-477a-bd9a-ec5f8d912281&amp;name=51fa712e-9de9-4b67-83f6-12667f4e2b7c-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="50745-9">
<a name="i4i_veterinary_indications_id_fb749112-65be-4cf9-a5d6-a093455629c8"></a><a name="section-4"></a><p></p>
<h1>Indications:</h1>
<p class="First">Vetmedin (pimobendan) is indicated for the management of the signs of mild, moderate, or severe (modified NYHA Class II<span class="Sup">a</span>, III<span class="Sup">b</span>, or IV<span class="Sup">c</span>) <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in dogs due to atrioventricular valvular insufficiency (AVVI) or <span class="product-label-link" type="condition" conceptid="4163710" conceptname="Dilated cardiomyopathy">dilated cardiomyopathy</span> (DCM).  Vetmedin is indicated for use with concurrent therapy for <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (e.g., furosemide, etc.) as appropriate on a case-by-case basis.  </p>
<p><span class="Sup">a</span> A dog with modified New York Heart Association (NYHA) Class II <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> has <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, etc. apparent when ordinary exercise is exceeded.</p>
<p><span class="Sup">b</span> A dog with modified NYHA Class III <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is comfortable at rest, but exercise capacity is minimal.</p>
<p><span class="Sup">c</span> A dog with modified NYHA Class IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> has no capacity for exercise and disabling clinical signs are present even at rest.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_d770b631-9e5d-4ece-b697-82af0d98552d"></a><a name="section-5"></a><p></p>
<h1>Dosage and Administration:</h1>
<p class="First">Vetmedin should be administered orally at a total daily dose of 0.23 mg/lb (0.5 mg/kg) body weight, using a suitable combination of whole or half tablets.  The total daily dose should be divided into 2 portions that are not necessarily equal, and the portions should be administered approximately 12 hours apart (i.e., morning and evening).  The tablets are scored and the calculated dosage should be provided to the nearest half tablet increment.  </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_ea022cd2-b1e8-4d16-80f3-f433ab86436f"></a><a name="section-6"></a><p></p>
<h1>Contraindications:</h1>
<p class="First">Vetmedin should not be given in cases of <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>, or any other clinical condition where an augmentation of <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> is inappropriate for functional or anatomical reasons. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_e70cb744-0d35-4650-b4ef-ed12aba96d92"></a><a name="section-7"></a><p></p>
<h1>Warnings:</h1>
<p class="First">Only for use in dogs with clinical evidence of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.  At 3 and 5 times the recommended dosage, administered over a 6-month period of time, pimobendan caused an exaggerated hemodynamic response in the normal dog heart, which was associated with cardiac pathology (See <span class="Bold"><a href="#i4i_animal_pharmacology_id_ea5711ea-f5a5-4704-9970-c5b6b1f37d59">Animal Safety</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_1ab426ce-0023-4226-bfc4-5a405c9bd4cf"></a><a name="section-8"></a><p></p>
<h1>Human Warnings:</h1>
<p class="First">Not for use in humans.  Keep this and all medications out of reach of children.  Consult a physician in case of accidental ingestion by humans.  </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_ea0eddd4-1139-4123-be80-a2428ac8355e"></a><a name="section-9"></a><p></p>
<h1>Precautions:</h1>
<p class="First">The safety of Vetmedin has not been established in dogs with asymptomatic heart disease or in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> caused by etiologies other than AVVI or DCM.  The safe use of Vetmedin has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches.  </p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_f3078326-2c57-4896-839d-0b7822dc4bcd"></a><a name="section-10"></a><p></p>
<h1>Adverse Reactions:</h1>
<p class="First">Clinical findings/adverse reactions were recorded in a 56-day field study of dogs with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) due to AVVI (256 dogs) or DCM (99 dogs).  Dogs were treated with either Vetmedin (175 dogs) or the active control enalapril maleate (180 dogs).  Dogs in both treatment groups received additional background cardiac therapy (See <span class="Bold"><a href="#i4i_clinical_studies_id_588503fe-8ab8-4ed2-8433-3f65f8dbfbd6">Effectiveness</a></span> for details and the difference in digoxin administration between treatment groups).</p>
<p>The Vetmedin group had the following prevalence (percent of dogs with at least one occurrence) of common adverse reactions/new clinical findings (not present in a dog prior to beginning study treatments): poor appetite (38%), <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> (33%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (30%), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (29%), <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> (14%), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> (13%), <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> (10%), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (9%), <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (7%), <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> (6%), <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> (6%), and <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">heart murmur</span> (3%).  Prevalence was similar in the active control group.  The prevalence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> was higher in the active control group (4%) compared to the Vetmedin group (1%).</p>
<p>Adverse reactions/new clinical findings were seen in both treatment groups and were potentially related to CHF, the therapy of CHF, or both.  The following adverse reactions/new clinical findings are listed according to body system and are not in order of prevalence: CHF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, chordae tendineae rupture, left atrial tear, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> overall, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, weak pulses, <span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulses</span>, increased <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4091505" conceptname="Gagging">gagging</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="4296301" conceptname="Hepatic congestion">hepatic congestion</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, collapse, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">trembling</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, increased water consumption, increased urination, urinary <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span>, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, abnormal serum electrolyte, protein, and glucose values, mild increases in serum hepatic enzyme levels, and mildly decreased platelet counts.  </p>
<p>See Table 1 for mortality due to CHF (including euthanasia, natural <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) and for the development of new <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (not present in a dog prior to beginning study treatments) by treatment group and type of heart disease (AVVI or DCM) in the 56-day field study.</p>
<a name="_RefIDDAE97D4346124B049CFD46D799561B4D"></a><table>
<caption><span>Table 1: CHF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> and New <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> in the 56-Day Field Study </span></caption>
<col width="40%">
<col width="27%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Vetmedin Group</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Active Control Group</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Dogs that died due to CHF</span></p></td>
<td class="Botrule Lrule" align="center" valign="top">
<p class="First">14.3%</p>
<p>n = 175</p>
<p>9 of 126 dogs with AVVI</p>
<p>16 of 49 dogs with DCM</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">14.4%</p>
<p>n = 180</p>
<p>16 of 130 dogs with AVVI</p>
<p>10 of 50 dogs with DCM</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Dogs that developed new <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span><span class="Sup">a</span></span></p></td>
<td class="Botrule Lrule" align="center" valign="top">
<p class="First">39.4%</p>
<p>n = 175</p>
<p>45 of 126 dogs with AVVI</p>
<p>24 of 49 dogs with DCM</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">45.0%</p>
<p>n = 180</p>
<p>59 of 130 dogs with AVVI</p>
<p>22 of 50 dogs with DCM</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> New <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> included <span class="product-label-link" type="condition" conceptid="441872" conceptname="Supraventricular premature beats">supraventricular premature beats</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, ventricular <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">premature beats</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>.</p>
<p>Following the 56-day masked field study, 137 dogs in the Vetmedin group were allowed to continue on Vetmedin in an open-label extended-use study without restrictions on concurrent therapy.  The adverse reactions/new clinical findings in the extended-use study were consistent with those reported in the 56-day study, with the following exception: One dog in the extended-use study developed acute cholestatic <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> after 140 days on Vetmedin and furosemide.  </p>
<p>In foreign post-approval drug experience reporting, the following additional suspected adverse reactions were reported in dogs treated with a capsule formulation of pimobendan: <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, excited behavior, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
<p>To report suspected adverse reactions, to obtain a Material Safety Data Sheet, or for technical assistance call 1-866-638-2226.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_dddea338-2c39-4089-a8cb-af82730386b0"></a><a name="section-11"></a><p></p>
<h1>Clinical Pharmacology:</h1>
<p class="First">Pimobendan is oxidatively demethylated to a pharmacologically active metabolite which is then conjugated with sulfate or glucuronic acid and excreted mainly via feces.  The mean extent of protein binding of pimobendan and the active metabolite in dog plasma is &gt;90%.  Following a single oral administration of 0.25 mg/kg Vetmedin tablets the maximal mean (± 1 SD) plasma concentrations (Cmax) of pimobendan and the active metabolite were 3.09 (0.76) ng/ml and 3.66 (1.21) ng/ml, respectively.  Individual dog Cmax values for pimobendan and the active metabolite were observed 1 to 4 hours post-dose (mean: 2 and 3 hours, respectively).  The total body clearance of pimobendan was approximately 90 mL/min/kg, and the terminal elimination half-lives of pimobendan and the active metabolite were approximately 0.5 hours and 2 hours, respectively.  Plasma levels of pimobendan and active metabolite were below quantifiable levels by 4 and 8 hours after oral administration, respectively.  The steady-state volume of distribution of pimobendan is 2.6 L/kg indicating that the drug is readily distributed into tissues.  Food decreased the bioavailability of an aqueous solution of pimobendan, but the effect of food on the absorption of pimobendan from Vetmedin tablets is unknown. </p>
<p>In normal dogs instrumented with left ventricular (LV) pressure transducers, pimobendan increased LV dP/dtmax (a measure of contractility of the heart) in a dose dependent manner between 0.1 and 0.5 mg/kg orally.  The effect was still present 8 hours after dosing.  There was a delay between peak blood levels of pimobendan and active metabolite and the maximum physiologic response (peak LV dP/dtmax).  Blood levels of pimobendan and active metabolite began to drop before maximum contractility was seen.  Repeated oral administration of pimobendan did not result in evidence of <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span> (decreased positive inotropic effect) or drug accumulation (increased positive inotropic effect).  Laboratory studies indicate that the positive inotropic effect of pimobendan may be attenuated by the concurrent use of a β-adrenergic blocker or a calcium channel blocker.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_588503fe-8ab8-4ed2-8433-3f65f8dbfbd6"></a><a name="section-12"></a><p></p>
<h1>Effectiveness:</h1>
<p class="First">In a double-masked, multi-site, 56-day field study, 355 dogs with modified NYHA Class II, III, or IV CHF due to AVVI or DCM were randomly assigned to either the active control (enalapril maleate) or the Vetmedin (pimobendan) treatment group.  Of the 355 dogs, 52% were male and 48% were female; 72% were diagnosed with AVVI and 28% were diagnosed with DCM; 34% had Class II, 47% had Class III, and 19% had Class IV CHF.  Dogs ranged in age and weight from 1 to 17 years and 3.3 to 191 lb, respectively.  The most common breeds were mixed breed, Doberman Pinscher, Cocker Spaniel, Miniature/Toy Poodle, Maltese, Chihuahua, Miniature Schnauzer, Dachshund, and Cavalier King Charles Spaniel.  The 180 dogs (130 AVVI, 50 DCM) in the active control group received enalapril maleate (0.5 mg/kg once or twice daily), and all but 2 received furosemide.  Per protocol, all dogs with DCM in the active control group received digoxin.  The 175 dogs (126 AVVI, 49 DCM) in the Vetmedin group received pimobendan (0.5 mg/kg/day divided into 2 portions that were not necessarily equal, and the portions were administered approximately 12 hours apart), and all but 4 received furosemide.  Digoxin was optional for treating supraventricular <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmia</span> in either treatment group, as was the addition of a β-adrenergic blocker if digoxin was ineffective in controlling heart rate.  After initial treatment at the clinic on Day 1, dog owners were to administer the assigned product and concurrent medications for up to 56±4 days.</p>
<p>The determination of effectiveness (treatment success) for each case was based on improvement in at least 2 of the 3 following primary variables: modified NYHA classification, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> score by a masked veterinary radiologist, and the investigator’s overall clinical effectiveness score (based on physical examination, radiography, electrocardiography, and clinical pathology).  Attitude, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, activity level, furosemide dosage change, cardiac size, body weight, survival, and owner observations were secondary evaluations contributing information supportive to product effectiveness and safety.</p>
<p>Based on protocol compliance and individual case integrity, 265 cases (134 Vetmedin, 131 active control) were evaluated for treatment success on Day 29.  See Table 2 for effectiveness results.</p>
<a name="_RefID8D9390B84F674024A1DED2869C2F8CA7"></a><table>
<caption><span>Table 2: Effectiveness Results for the 56-Day Field Study </span></caption>
<col width="52%">
<col width="25%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Vetmedin Group</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Active Control Group</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Treatment Success on Day 29</span></p></td>
<td class="Botrule Lrule" align="center" valign="top">
<p class="First">80.7%</p>
<p>n = 134</p>
<p>88 of 101 dogs with AVVI</p>
<p>20 of 33 dogs with DCM</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">76.3%</p>
<p>n = 131</p>
<p>77 of 100 dogs with AVVI</p>
<p>23 of 31 dogs with DCM</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Treatment Success on Day 56</span></p></td>
<td class="Botrule Lrule" align="center" valign="top">
<p class="First">71.1%</p>
<p>n = 113</p>
<p>66 of 85 dogs with AVVI</p>
<p>13 of 28 dogs with DCM</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">67.2%</p>
<p>n = 110</p>
<p>56 of 85 dogs with AVVI</p>
<p>17 of 25 dogs with DCM</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">No increase in furosemide dose between Day 1 and Day 29</span></p></td>
<td class="Botrule Lrule" align="center" valign="top">
<p class="First">78.3%</p>
<p>n = 130</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">68.6%</p>
<p>n = 126</p>
</td>
</tr>
</tbody>
</table>
<p>At the end of the 56-day study, dogs in the Vetmedin group were enrolled in an unmasked field study to monitor safety under extended use, without restrictions on concurrent medications. </p>
<p>Vetmedin was used safely in dogs concurrently receiving furosemide, digoxin, enalapril, atenolol, spironolactone, nitroglycerin, hydralazine, diltiazem, antiparasitic products (including heartworm prevention), antibiotics (metronidazole, cephalexin, amoxicillin-clavulanate, fluoroquinolones), topical ophthalmic and otic products, famotidine, theophylline, levothyroxine sodium, diphenhydramine, hydrocodone, metoclopramide, and butorphanol, and in dogs on sodium-restricted diets.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_2f7ef7c8-a30e-4d5f-828c-a1f995e14767"></a><a name="section-13"></a><p></p>
<h1>Palatability:</h1>
<p class="First">In a laboratory study, the palatability of Vetmedin was evaluated in 20 adult female Beagle dogs offered doses twice daily for 14 days.  Ninety percent (18 of 20 dogs) voluntarily consumed more than 70% of the 28 tablets offered.  Including two dogs that consumed only 4 and 7% of the tablets offered, the average voluntary consumption was 84.2%.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_ea5711ea-f5a5-4704-9970-c5b6b1f37d59"></a><a name="section-14"></a><p></p>
<h1>Animal Safety:</h1>
<p class="First">In a laboratory study, Vetmedin chewable tablets were administered to 6 healthy Beagles per treatment group at 0 (control), 1, 3, and 5 times the recommended dosage for 6 months.  See Table 3 for cardiac pathology results.  The cardiac pathology/histopathology noted in the 3X and 5X dose groups is typical of positive inotropic and vasodilator <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span> in normal dog hearts, and is associated with exaggerated hemodynamic responses to these drugs.  None of the dogs developed signs of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and there was no mortality.  </p>
<a name="_RefIDC95B8A8308984043A9AE588889DB84A5"></a><table>
<caption><span>Table 3: Incidence of Cardiac Pathology/Histopathology in the Six-month Safety Study </span></caption>
<col width="76%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First">Severe <span class="product-label-link" type="condition" conceptid="4184746" conceptname="Left ventricular hypertrophy">left ventricular hypertrophy</span> with multifocal subendocardial ischemic lesions</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">One 3X and     two 5X dogs<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Moderate to marked myxomatous thickening of the mitral valves</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Three 5X dogs</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Myxomatous thickening of the chordae tendineae</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">One 3X and    two 5X dogs</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Endocardial thickening of the left ventricular outflow tract</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">One 1X, two 3X, and two 5X dogs</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Left atrial endocardial thickening (jet lesions) in 2 of the dogs that developed murmurs of mitral valve insufficiency</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">One 3X and one 5X dog</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Granulomatous inflammatory lesion in the right atrial myocardium</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">One 3X dog</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Most of the gross and histopathologic findings occurred in these three dogs</p>
<p>Murmurs of mitral valve insufficiency were detected in one 3X (Day 65) and two 5X dogs (Days 135 and 163). These murmurs (grades II-III of VI) were not associated with clinical signs.</p>
<p>Indirect blood pressure was unaffected by Vetmedin at the label dose (1X).  Mean diastolic blood pressure was decreased in the 3X group (74 mmHg) compared to the control group (82 mmHg).  Mean systolic blood pressure was decreased in the 5X group (117 mmHg) compared to the control group (124 mmHg).  None of the dogs had clinical signs of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.  </p>
<p>On 24-hour Holter monitoring, mean heart rate was increased in the 5X group (101 beats/min) compared to the control group (94 beats/min).  Not counting escape beats, the 3X and 5X groups had slightly higher numbers of isolated ventricular ectopic complexes (VEs).  The maximum number of non-escape VEs recorded either at baseline or in a control group dog was 4 VEs/24 hours.  At either Week 4 or Week 20, three 3X group dogs had maximums of 33, 13, and 10 VEs/24 hours, and two 5X group dogs had maximums of 22 and 9 VEs/24 hours.  One 1X group dog with no VEs at baseline had 6 VEs/24 hours at Week 4 and again at Week 20.  Second-degree atrioventricular <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> was recorded in one 3X group dog at Weeks 4 and 20, and in one dog from each of the 1X and 5X groups at Week 20.  None of the dogs had clinical signs associated with these electrocardiogram changes.</p>
<p>Treatment was associated with small differences in mean platelet counts (decreased in the 3X and 1X groups), potassium (increased in the 5X group), glucose (decreased in the 1X and 3X groups), and maximum blood glucose in glucose curves (increased in the 5X group).  All individual values for these variables were within the normal range.  Three 1X and one 5X group dogs had mild elevations of alkaline phosphatase (less than two times normal).</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose stools</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> were infrequent and self-limiting. </p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_269c6e71-fc65-4545-8668-6420540e376d"></a><a name="section-15"></a><p></p>
<h1>Storage Information:</h1>
<p class="First">Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (between 59° and 86°F).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_1c13eeeb-661c-4df6-b2e2-d41f163da59a"></a><a name="section-16"></a><p></p>
<h1>How Supplied:</h1>
<p class="First">Vetmedin (pimobendan) Chewable Tablets:</p>
<p>Available as 1.25, 2.5, 5 and 10 mg oblong half-scored chewable tablets – 50 tablets per bottle.</p>
<p>NDC 0010-4480-01 - 1.25 mg - 50 tablets</p>
<p>NDC 0010-4481-01 – 2.5 mg – 50 tablets</p>
<p>NDC 0010-4482-01 - 5 mg - 50 tablets</p>
<p>NDC 0010-4479-01 – 10 mg – 50 tablets</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ee5d5783-21ab-4d3c-aeb6-1c8372b8f694"></a><a name="section-17"></a><p></p>
<p class="First">Vetmedin is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, licensed to Boehringer Ingelheim Vetmedica, Inc.</p>
<p>Copyright © 2013 Boehringer Ingelheim Vetmedica, Inc. or an affiliated company. All Rights Reserved.</p>
<p>Manufactured for:<br>Boehringer Ingelheim Vetmedica, Inc.<br>St. Joseph, MO 64506 U.S.A.</p>
<p>448005-00</p>
<p>Revised 06/2013<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_d25eb557-43be-433e-b676-01d9a89516ae"></a><a name="section-18"></a><p></p>
<h1>Container Label, 1.25 mg, 50 Tablets</h1>
<div class="Figure">
<a name="id6905474"></a><img alt="Picture of container label for 1.25 mg tablets." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5441e5b2-cdc0-477a-bd9a-ec5f8d912281&amp;name=51fa712e-9de9-4b67-83f6-12667f4e2b7c-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_a3364ff8-c28f-4359-a35c-8712fb76b51a"></a><a name="section-19"></a><p></p>
<h1>Display Carton, 1.25 mg, 50 Tablets</h1>
<div class="Figure">
<a name="id6905846"></a><img alt="Picture of display carton for 1.25 mg tablets." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5441e5b2-cdc0-477a-bd9a-ec5f8d912281&amp;name=51fa712e-9de9-4b67-83f6-12667f4e2b7c-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_03435775-2c53-4e57-bb6a-238967fed9e9"></a><a name="section-20"></a><p></p>
<h1>Container Label, 2.5 mg, 50 Tablets</h1>
<div class="Figure">
<a name="id6906795"></a><img alt="Picture of container label for 2.5 mg tablets." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5441e5b2-cdc0-477a-bd9a-ec5f8d912281&amp;name=51fa712e-9de9-4b67-83f6-12667f4e2b7c-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_a274e0c6-f44d-43ab-a2fb-4766d50c2698"></a><a name="section-21"></a><p></p>
<h1>Display Carton, 2.5 mg, 50 Tablets</h1>
<div class="Figure">
<a name="id6907217"></a><img alt="Picture of display carton for 2.5 mg tablets." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5441e5b2-cdc0-477a-bd9a-ec5f8d912281&amp;name=51fa712e-9de9-4b67-83f6-12667f4e2b7c-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_40a5a2d2-1c76-4c75-b1e1-b18d2ecd1e52"></a><a name="section-22"></a><p></p>
<h1>Container Label, 5 mg, 50 Tablets</h1>
<div class="Figure">
<a name="id6904751"></a><img alt="Picture of container label for 5 mg tablet." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5441e5b2-cdc0-477a-bd9a-ec5f8d912281&amp;name=51fa712e-9de9-4b67-83f6-12667f4e2b7c-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_33b73bf1-f2df-40e6-bc8b-e7d8a92a3ab0"></a><a name="section-23"></a><p></p>
<h1>Display Carton, 5 mg, 50 Tablets</h1>
<div class="Figure">
<a name="id6904752"></a><img alt="Picture of display carton for 5 mg tablets." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5441e5b2-cdc0-477a-bd9a-ec5f8d912281&amp;name=51fa712e-9de9-4b67-83f6-12667f4e2b7c-07.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_31414019-e593-4450-a68f-bbf076c2cb35"></a><a name="section-24"></a><p></p>
<h1>Container Label, 10 mg, 50 Tablets</h1>
<div class="Figure">
<a name="id6908885"></a><img alt="Picture of container label for 10 mg tablets." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5441e5b2-cdc0-477a-bd9a-ec5f8d912281&amp;name=51fa712e-9de9-4b67-83f6-12667f4e2b7c-08.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_de4f653d-aab8-4d1c-8d44-2ca9ff09ccda"></a><a name="section-25"></a><p></p>
<h1>Display Carton, 10 mg, 50 Tablets</h1>
<div class="Figure">
<a name="id6908887"></a><img alt="Picture of display carton for 10 mg tablets." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5441e5b2-cdc0-477a-bd9a-ec5f8d912281&amp;name=51fa712e-9de9-4b67-83f6-12667f4e2b7c-09.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VETMEDIN 		
					</strong><br><span class="contentTableReg">pimobendan tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0010-4480</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PIMOBENDAN</strong> (PIMOBENDAN) </td>
<td class="formItem">PIMOBENDAN</td>
<td class="formItem">1.25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">MEAT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0010-4480-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141273</td>
<td class="formItem">08/04/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VETMEDIN 		
					</strong><br><span class="contentTableReg">pimobendan tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0010-4481</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PIMOBENDAN</strong> (PIMOBENDAN) </td>
<td class="formItem">PIMOBENDAN</td>
<td class="formItem">2.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">MEAT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0010-4481-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141273</td>
<td class="formItem">04/03/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VETMEDIN 		
					</strong><br><span class="contentTableReg">pimobendan tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0010-4482</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PIMOBENDAN</strong> (PIMOBENDAN) </td>
<td class="formItem">PIMOBENDAN</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">MEAT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0010-4482-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141273</td>
<td class="formItem">08/04/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VETMEDIN 		
					</strong><br><span class="contentTableReg">pimobendan tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0010-4479</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PIMOBENDAN</strong> (PIMOBENDAN) </td>
<td class="formItem">PIMOBENDAN</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">28mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">MEAT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0010-4479-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141273</td>
<td class="formItem">04/03/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Boehringer Ingelheim Vetmedica, Inc.
							(007134091)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>51fa712e-9de9-4b67-83f6-12667f4e2b7c</div>
<div>Set id: 5441e5b2-cdc0-477a-bd9a-ec5f8d912281</div>
<div>Version: 3</div>
<div>Effective Time: 20140418</div>
</div>
</div> <div class="DistributorName">Boehringer Ingelheim Vetmedica, Inc.</div></p>
</body></html>
